Breast Cancer Clinical Trials

Study Title: NRG-BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Primary/Site/Co-Investigator: Marie Wood, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4101
Study Title: NSABP B-55:  A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA 1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Primary/Site/Co-Investigator: Marie Wood, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4101
Study Title:
VCC 0601 – Phase I/II Trial to Evaluate Partial Breast Radiation to the Region of the Lumpectomy Cavity Using Intensity Modulated Radiation Therapy (IMRT) in Elderly Women with Breast Cancer
Primary/Site/Co Investigator: Ruth Heimann, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4101
Study Title: A011106 – ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study
Primary/Site/Co Investigator: Farrah Khan, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4101
Study Title: S1207:  Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year  of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
Primary/Site/Co Investigator: Marie Wood, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4101
Study Title: A011202A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection toAxillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have PositiveSentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Primary/Site/Co Investigator: Michelle Sowden, DO
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4101
Study Title: A011502: A Randomized Phase III Double Blind Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
Primary/Site/Co-Investigator: Marie Wood, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4101
Study Title: AFT25 COMET: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial
Primary/Site/Co-Investigator: Jessica Cintolo-Gonzalez, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4101

Colon Cancer Clinical Trials

Study Title: S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
Primary/Site/Co-Investigator: Krista Evans, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4101

Kidney Cancer Clinical Trials

Study Title: EA8143: A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Primary/Site/Co-Investigator: Scott Perrapato, DO, FACOS
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4101

Lung Cancer Clinical Trials

Study Title: SWOG 1400: Phase II/III Biomarker Driven Master Protocol for Second-Line Therapy of Squamous Cell Lung Cancer
Primary/Site/Co-Investigator: Hibba Rehman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4101
Study Title: A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) 
Primary/Site/Co-Investigator: Hibba Rehman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4101
Study Title: ECOG-ACRIN E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Primary/Site/Co Investigator: Hibba Rehman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4101
Study Title: ECOG EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Primary/Site/Co Investigator: Hibba Rehman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4101
Study Title: TAHOE M16-289: A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared with Topotecan for High DLL3 Expressing Small Cell Lung Cancer (SCLC) Subjects with First Relapse/Recurrence Following Front-Line Platinum-Based Chemotherapy (TAHOE) 
Primary/Site/Co Investigator: Farrah Khan, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4101
 

Myeloma Clinical Trials

Study Title: E1A11 (ENDURANCE): Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus CarfAlzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma
Primary/Site/Co-Investigator: Julian Sprague, MD, PhD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4101

Multiple Cancer Sites Clinical Trials

Study Title: A8081001: Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study of Pf-02341066, A C-met/Hgfr Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer
Primary/Site/Co-Investigator: Steven Ades, MD, MSc
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4101
Study Title: EAY131 (MATCH): Molecular Analysis for Therapy Choice (MATCH), Master Protocol 
Primary/Site/Co-Investigator: Marc Greenblatt, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4101
Study Title: S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors
Primary/Site/Co Investigator: Hibba Rehman, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4101
Study Title: AFT28 CANVAS: Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A randomized Effectiveness Trial (CANVAS trial)
Primary/Site/Co Investigator: Chris Holmes, MD, PhD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4101

Prostate Cancer Clinical Trials

Study Title: NRG GU005: Phase III Image-Guided RadiationTherapy (IGRT) and Stereotactic Body Radiation Therapy (SBRT) vs. IGRT and Hypofractionated Intensity-Modulated Radiation Therapy (IMRT) for localized intermediate risk prostate cancer
Primary/Site/Co-Investigator: Nataniel Lester-Coll, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4101
Study Title: RTOG 0924: Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate and Favorable High-Risk Prostate Cancer: A Phase III Randomized Trial
Primary/Site/Co-Investigator: H. James Wallace III, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4101

Rectum Cancer Clinical Trials

Study Title: Alliance Trial PROSPECT N1048: A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Res
Primary/Site/Co-Investigator: Steven Ades, MD, MSc
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4101
Study Title: MSKCC 13213: A phase II multicenter randomized trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or non-operative manage
Primary/Site/Co-Investigator: Peter Cataldo, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4101

Sarcoma and Soft Tissue Cancer Clinical Trials

Study Title: A091304: A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma
Primary/Site/Co-Investigator: Farrah Khan, MD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4101

Symptom Management, Survivorship, and Basic Science Cancer Clinical Trials

Study Title: Venous thromboembolism (VTE) prevention in patients with malignant glioma
Primary/Site/Co-Investigator: Alissa Thomas, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802) 656-4101
To Learn More or Enroll: Call (802)656-4101
Study Title: Alternative exercise program to improve skeletal muscle function and fatigue in cancer survivors
Primary/Site/Co-Investigator: Michael Toth, PhD
For more Information About this Trial on ClinicalTrials.gov: Click Here
To Learn More or Enroll: Call (802)656-4101
Study Title: Predictors of Dyspnea/fatigue Syndrome in Breast Cancer Survivors
Primary/Site/Co Investigator: Kim Dittus, MD, PhD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802) 656-4101
To Learn More or Enroll: Call (802)656-4101
Study Title: Quality of Life Assessment for Head and Neck Cancer Patients Undergoing Treatment in the First Year of Survivorship
Primary/Site/Co Investigator: Maura Barry, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802) 656-4101
To Learn More or Enroll: Call (802)656-4101
Study Title: Efficacy of a Novel Biofeedback Motivational Intervention for Smoking Cessation 
Primary/Site/Co Investigator: Garth Garrison, MD
For more Information: call the UVM Cancer Center Clinical Trials Office at (802) 656-4101
To Learn More or Enroll: Call (802)656-4101
 

About Us

FAQs

Contact Us

Trials by Cancer Type

Click below to view open cancer trials by type. 

BreastColonKidneyLungMyelomaMultiple SitesPediatric ProstateRectumSarcoma and Soft TissueSymptom Management, Survivorship, and Basic Science

Enroll Now

If you have any questions or would like to enroll in one of these clinical trials, please call (802) 656-4101.